Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase) also known as vascular endothelial growth factor receptor 2 (VEGFR-2) is a VEGF receptor. KDR is the human gene encoding it. KDR has also been designated as CD309 (cluster of differentiation 309). KDR is also known as Flk1 (Fetal Liver Kinase 1).
Quick Facts KDR, Available structures ...
KDR |
---|
|
Available structures |
---|
PDB | Ortholog search: PDBe RCSB |
---|
List of PDB id codes |
---|
1VR2, 1Y6A, 1Y6B, 1YWN, 2M59, 2MET, 2MEU, 2OH4, 2P2H, 2P2I, 2QU5, 2QU6, 2RL5, 2X1W, 2X1X, 2XIR, 3B8Q, 3B8R, 3BE2, 3C7Q, 3CJF, 3CJG, 3CP9, 3CPB, 3CPC, 3DTW, 3EFL, 3EWH, 3KVQ, 3S35, 3S36, 3S37, 3U6J, 3VHE, 3VHK, 3VID, 3VNT, 3VO3, 3WZD, 3WZE, 4AG8, 4AGC, 4AGD, 4ASD, 4ASE, 5EW3 |
|
|
Identifiers |
---|
Aliases | KDR, CD309, FLK1, VEGFR, VEGFR2, Kinase insert domain receptor |
---|
External IDs | OMIM: 191306; MGI: 96683; HomoloGene: 55639; GeneCards: KDR; OMA:KDR - orthologs |
---|
|
|
|
|
|
Wikidata |
|
Close
The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.[5]
Kinase insert domain receptor has been shown to interact with SHC2,[6] Annexin A5[7] and SHC1.[8][9]
Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F (August 2011). "Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer". Clinical Cancer Research. 17 (16): 5257–67. doi:10.1158/1078-0432.CCR-11-0379. PMC 3156871. PMID 21712447.
- Holmes K, Roberts OL, Thomas AM, Cross MJ (October 2007). "Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition". Cellular Signalling. 19 (10): 2003–12. doi:10.1016/j.cellsig.2007.05.013. PMID 17658244.
- Petrova TV, Makinen T, Alitalo K (November 1999). "Signaling via vascular endothelial growth factor receptors". Experimental Cell Research. 253 (1): 117–30. doi:10.1006/excr.1999.4707. PMID 10579917.
- Wang J, Fu X, Jiang C, Yu L, Wang M, Han W, Liu L, Wang J (May 2014). "Bone marrow mononuclear cell transplantation promotes therapeutic angiogenesis via upregulation of the VEGF-VEGFR2 signaling pathway in a rat model of vascular dementia". Behavioural Brain Research. 265: 171–80. doi:10.1016/j.bbr.2014.02.033. PMC 4000455. PMID 24589546.
- Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, Shibuya M (May 2000). "Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction". Annals of the New York Academy of Sciences. 902 (1): 201–5, discussion 205–7. Bibcode:2000NYASA.902..201S. doi:10.1111/j.1749-6632.2000.tb06314.x. PMID 10865839. S2CID 11488629.
- Zachary I, Gliki G (February 2001). "Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family". Cardiovascular Research. 49 (3): 568–81. doi:10.1016/S0008-6363(00)00268-6. PMID 11166270.
- Vené R, Benelli R, Noonan DM, Albini A (2001). "HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis". Clinical & Experimental Metastasis. 18 (7): 533–8. doi:10.1023/A:1011991906685. PMID 11688957. S2CID 24787929.
- Lenton K (2003). "VEGFR-2 (KDR/Flk-1)". Journal of Biological Regulators and Homeostatic Agents. 16 (3): 227–32. PMID 12456025.
- Matsumoto T, Mugishima H (June 2006). "Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis". Journal of Atherosclerosis and Thrombosis. 13 (3): 130–5. doi:10.5551/jat.13.130. PMID 16835467.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.